Skip to main content
. 2020 Oct 2;56(3):605–613. doi: 10.1038/s41409-020-01069-w

Fig. 2. Univariable comparisons of progression-free survival for selected risk factors were done by log-rank tests.

Fig. 2

a Shows progression-free survival by sensitivity to chemoimmunotherapy (CIT). Patients who were not exposed to CIT are shown in green, patients with CIT-sensitive CLL in brown and patients with poorly responsive/refractory CLL in violet. b Shows PFS by pathway-inhibitor failure. Patients who had only been exposed to idelalisib and responsive disease are displayed in green, all remaining patients are displayed in violet. c Shows PFS of patients by pathway-inhibitor (PI)- or CIT failure. Patients who had failed neither PI nor CIT are shown in green. Patients who had failed either PI or CIT are shown in brown color. The remaining patients (violet curve), who have failed both, CIT and PI, have the worst outcome.